The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
06 2021
Historique:
received: 11 10 2020
revised: 16 01 2021
accepted: 03 03 2021
pubmed: 19 4 2021
medline: 30 9 2021
entrez: 18 4 2021
Statut: ppublish

Résumé

The incidence of autoimmune diseases is increasing worldwide, thus stimulating studies on their etiopathogenesis, derived from a complex interaction between genetic and environmental factors. Genetic association studies have shown the PTPN22 gene as a shared genetic risk factor with implications in multiple autoimmune disorders. By encoding a protein tyrosine phosphatase expressed by the majority of cells belonging to the innate and adaptive immune systems, the PTPN22 gene may have a fundamental role in the development of immune dysfunction. PTPN22 polymorphisms are associated with rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus, and many other autoimmune conditions. In this review, we discuss the progress in our understanding of how PTPN22 impacts autoimmunity in both humans and animal models. In addition, we highlight the pathogenic significance of the PTPN22 gene, with particular emphasis on its role in T and B cells, and its function in innate immune cells, such as monocytes, dendritic and natural killer cells. We focus particularly on the complexity of PTPN22 interplay with biological processes of the immune system. Findings highlight the importance of studying the function of disease-associated PTPN22 variants in different cell types and open new avenues of investigation with the potential to drive further insights into mechanisms of PTPN22. These new insights will reveal important clues to the molecular mechanisms of prevalent autoimmune diseases and propose new potential therapeutic targets.

Identifiants

pubmed: 33866147
pii: S0049-0172(21)00034-2
doi: 10.1016/j.semarthrit.2021.03.004
pii:
doi:

Substances chimiques

PTPN22 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 22 EC 3.1.3.48

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

513-522

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have declared that no competing interest exists.

Auteurs

Kalthoum Tizaoui (K)

Department of Basic Sciences, Division of Histology and Immunology, Faculty of Medicine Tunis, Tunis El Manar University, Tunis 1068, Tunisia.

Salvatore Terrazzino (S)

Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte Orientale, Novara, Italy.

Sarah Cargnin (S)

Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte Orientale, Novara, Italy.

Keum Hwa Lee (KH)

Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.

Philipp Gauckler (P)

Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

Han Li (H)

University of Florida College of Medicine, Gainesville, FL 32610, United States.

Jae Il Shin (JI)

Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Electronic address: shinji@yuhs.ac.

Andreas Kronbichler (A)

Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH